Patent intelligence · US
US 2020318108
MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)
MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)
Patent details — US 2020318108
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 8, 2020
- Expiration
- Oct 3, 2040
- Applicant
- CRISPR THERAPEUTICS AG [CH]
- CPC classes
- A61K 35/ 12 A I, A61K 48/ 00 A I, A61K/3512, A61K/480066
Quick answer
US 2020318108 (MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)) is held by CRISPR THERAPEUTICS AG [CH]. Status: granted. Granted Oct 8, 2020. Expires Oct 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG [CH]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 35/ 12 A I, A61K 48/ 00 A I, A61K/3512, A61K/480066, A61P 27/ 02 A I, A61P/2702
More from CRISPR THERAPEUTICS AG [CH]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 2020318108?
US 2020318108 (MATERIALS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 2A AND/OR NON-SYNDROMIC AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA (ARRP)) is held by CRISPR THERAPEUTICS AG [CH]. Status: granted. Granted Oct 8, 2020. Expires Oct 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2020318108?
CRISPR THERAPEUTICS AG [CH] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 2020318108 expire?
Our index shows an expiration date of Oct 3, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.